piroxantrone

01/01/1994 - "Phase II trial of piroxantrone in metastatic gastric adenocarcinoma."
11/01/1993 - "A phase II trial of piroxantrone in adenocarcinoma of the pancreas. "
01/01/1994 - "Piroxantrone has minimal activity against gastric adenocarcinoma and no further investigation of this agent on this schedule in this disease is recommended."
01/01/1994 - "Twenty-one evaluable patients with advanced gastric adenocarcinoma were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. "
11/01/1993 - "Thirty-five evaluable patients with advanced adenocarcinoma of the pancreas were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. "

01/01/1994 - "Phase II trial of piroxantrone in gastric carcinoma. "
06/01/1995 - "A phase II trial of the new anthrapyrazole piroxantrone was conducted by the Southwest Oncology Group in advanced ovarian carcinoma. "
06/01/1995 - "A phase II trial of piroxantrone in advanced ovarian carcinoma after failure of platinum-based chemotherapy: Southwest Oncology Group Study 8904."

11/01/1993 - "Based on the observed response rate and cardiac toxicity, further trials of piroxantrone in the treatment of soft tissue sarcoma do not appear warranted."
09/01/1993 - "Seven patients developed symptomatic congestive heart failure (CHF) at cumulative piroxantrone doses ranging from 855 to 2,475 mg/m2 and two have died of cardiotoxicity. "
09/15/1994 - "The clear association with cardiac toxicity combined with the relatively low efficacy led to the conclusion that piroxantrone cannot be recommended for further development as therapy for women with breast cancer. "
11/01/1999 - "Their cardiotoxicity may result from the formation of iron(III) complexes of losoxantrone and piroxantrone. "
08/07/1987 - "Oxantrazole is an anthrapyrazole analogue developed as an anthracycline-like agent with potentially reduced cardiotoxicity. "

01/01/1994 - "Phase II trial of piroxantrone in metastatic breast cancer. "
09/15/1994 - "A Phase II clinical trial was conducted in 30 women with metastatic breast cancer in whom piroxantrone was administered at a dose of 160 mg/m2 by 1-hour infusion. "
01/01/1994 - "We conclude that piroxantrone given at this dose and schedule has minimal activity in patients with metastatic breast cancer."
09/15/1994 - "Evaluation of piroxantrone in women with metastatic breast cancer and failure on nonanthracycline chemotherapy."
09/15/1994 - "The clear association with cardiac toxicity combined with the relatively low efficacy led to the conclusion that piroxantrone cannot be recommended for further development as therapy for women with breast cancer. "

04/01/1992 - "Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung. "